OakChart

10x Genomics Inc

TXGHealthcare·Medical Devices·USA·Mid·NASD·Nov 11 • 8:10 AM ET

65.00+2.10 (3.34%)
2026-11-11 14:22 CET
Market cap
8,195.30 USD m
Revenue, TTM
618.58 USD m
Net income, TTM
-67.08 USD m
Free cash flow, TTM
93.77 USD m
EPS diluted, TTM
-0.52
P/E
-
Compare

Price

TXG against its 20, 50 and 200-day averages
2050200beat
20.0040.0060.0080.00100.004.7M9.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TXGclose 65.0020-day 69.5750-day 74.13200-day 42.2265.00

36.8% under 102.81 on 6 Oct 2026. Last 15 sessions, 58.2% high to low

Profile

TXG
52-week range, 57% of the way up
15.12102.81

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

IndexRUT
Employees1178
IPOSep 12, 2019
Beta2.04
ATR, 14d6.61
Rel volume0.01
Short float10.74%
Insider own10.85%
Inst own102.06%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap8.47B
Enterprise Value7.97B
Income-67.08M
Sales618.58M
Book/sh6.37
Cash/sh4.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1178
IPOSep 12, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S13.69
P/B10.20
P/C14.71
P/FCF90.32
EV/EBITDA-
EV/Sales12.88
Quick Ratio4.66
Current Ratio5.12
Debt/Eq0.09
LT Debt/Eq0.08
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.52
EPS next Y-0.67
EPS next Q-0.22
EPS this Y-79.20%
EPS next Y-7.16%
EPS next 5Y-1.94%
EPS past 3/5Y37.90% 42.10%
Sales past 3/5Y7.57% 16.55%
EPS Y/Y TTM16.67%
Sales Y/Y TTM-3.62%
EPS Q/Q32.16%
Sales Q/Q1.12%
EarningsNov 05 AMC
EPS/Sales Surpr.43.82% 1.83%

Ownership

Insider Own10.85%
Insider Trans-1.93%
Inst Own102.06%
Inst Trans5.09%
ROA-6.42%
ROE-8.27%
ROIC-7.44%
Gross Margin72.48%
Oper. Margin-11.47%
Profit Margin-10.84%
SMA20-6.57%
SMA50-12.32%
SMA20053.97%
Trades-

Technical

Shs Outstand121.41M
Shs Float116.15M
Short Float10.74%
Short Ratio3.65
Short Interest12.47M
52W High102.81 -36.78%
52W Low15.12 329.89%
Volatility10.16% 9.13%
ATR (14)6.61
RSI (14)45.15
Beta2.04
Rel Volume0.01
Avg Volume3.42M
Volume1,567

Performance

Perf Week-3.73%
Perf Month-9.46%
Perf Quarter11.78%
Perf Half Y208.50%
Perf YTD298.53%
Perf Year291.80%
Perf 3Y83.20%
Perf 5Y-61.29%
Perf 10Y-
Recom2.53
Target Price68.14
Prev Close62.90
Price65.00
Change %3.34%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 23, 2026DowngradeSStephensOverweight → Equal-Weight
Sep 28, 2026InitiatedAArgusBuy$110+69.2%
Sep 09, 2026ResumedUUBSNeutral$68+4.6%
Sep 01, 2026InitiatedRRBC Capital MktsSector Perform$70+7.7%
Mar 31, 2026UpgradeWWilliam BlairMkt Perform → Outperform
Dec 11, 2025DowngradeCCitigroupBuy → Neutral
Dec 02, 2025DowngradeMMorgan StanleyOverweight → Equal-Weight$20-69.2%
Sep 11, 2025InitiatedPPiper SandlerNeutral$15-76.9%
Feb 13, 2025DowngradeLLeerink PartnersOutperform → Market Perform$25 → $12-81.5%
Sep 03, 2024InitiatedLLeerink PartnersOutperform$35-46.2%

Peers

Mkt cap
TickerCompanyMkt cap
BRKRBruker Corp9.58B
BIOBio-Rad Laboratories Inc10.41B
ILMNIllumina Inc32.96B
TECHBio-Techne Corp11.41B
QTRXQuanterix Corp152.41M
PACBPacific Biosciences of California Inc722.86M
ALMRAlamar Biosciences Inc2.19B
LABStandard BioTools Inc267.79M
AAgilent Technologies Inc50.18B
TMOThermo Fisher Scientific Inc265.76B

Insider trading

latest 14 of 54
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
SULIMAN SHEHNAAZDirectorSep 22 '26Sale81.195,723464,66823,792Sep 24 04:30 PM
Saxonov SergeChief Executive OfficerSep 22 '26Sale81.2225,0002,030,5621,050,249Sep 24 04:29 PM
Shehnaaz SulimanAffiliateSep 22 '26Proposed Sale79.105,723452,689Sep 22 06:27 PM
Taich AdamChief Financial OfficerSep 09 '26Sale64.5746,3882,995,470316,344Sep 11 04:47 PM
ADAM TAICHOfficerSep 09 '26Proposed Sale64.5746,3882,995,470Sep 09 04:28 PM
STUELPNAGEL JOHN RDirectorSep 03 '26Sale61.7520,0001,235,072328,436Sep 08 07:00 PM
STUELPNAGEL JOHN RDirectorSep 03 '26Proposed Sale61.7520,0001,235,046Sep 03 02:28 PM
Saxonov SergeChief Executive OfficerAug 26 '26Sale63.6910,486667,9011,075,349Aug 28 07:22 PM
Serge SaxonovDirector, CEOAug 26 '26Proposed Sale62.1835,4862,206,654Aug 26 06:09 PM
Saxonov SergeChief Executive OfficerAug 24 '26Sale63.0218,5451,168,7751,085,835Aug 26 04:46 PM
Taich AdamChief Financial OfficerAug 24 '26Sale63.0217,1661,081,853362,732Aug 26 04:44 PM
Hindson Benjamin J.See RemarksAug 24 '26Sale63.0213,818870,860488,182Aug 26 04:43 PM
SULIMAN SHEHNAAZDirectorAug 24 '26Sale63.652,207140,47829,515Aug 26 04:42 PM
Taich AdamOfficerAug 24 '26Proposed Sale65.1216,6141,081,904Aug 24 06:53 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
VBVanguard Morningstar Small-Cap ETFAUM: 79.96B
IWMiShares Russell 2000 Index FundAUM: 78.30B
ARKGARK Genomic Revolution ETFAUM: 2.07B
ARKEARK DIET Q3 Buffer ETFAUM: 1.48M
ARKKARK Innovation ETFAUM: 6.12B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.56B
VXFVanguard Extended Market Index ETFAUM: 30.61B
IWOiShares Russell 2000 Growth ETFAUM: 14.20B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B

News

latest 14 of 206
  • Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform (PR Newswire)
  • 10x Genomics: Q3 Earnings Snapshot (Associated Press) -14.01%
  • 10x Genomics Beats And Raises On Margin Repair, But Flat Sales And Collapsing Instrument Revenue Leave Atera To Carry The Story (Earnings Whispers)
  • 10x Genomics Reports Third Quarter 2026 Financial Results (PR Newswire)
  • 10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis (PR Newswire) -12.10%
  • Loading…
  • 10x Genomics Faces A Steep Bar After 84% Rally As Raised Outlook Meets Flat Sales (Earnings Whispers) +7.18%
  • 10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference (PR Newswire) +6.94%
  • Cathie Wood-Led Ark Invest's Biggest Q3 Winners And Losers PLTR, NVDA, TXG Led While TSLA, RKLB Dragged (Stocktwits)
  • 10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026 (PR Newswire)
  • 10x Genomics and Fred Hutch partner on cancer technologies (Pharmaceutical Business Review)
  • 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers (PR Newswire) -5.65%
  • NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat (TIKR) -17.47%
  • Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies Unloads $18M Worth Of TWST Shares (Stocktwits)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.150-0.267-0.150150.67147.9614
2026Q22026-08-06-0.140-0.243-0.138151.04146.6714
2026Q12026-05-07-0.100-0.275-0.105150.84146.4116
2025Q42026-02-12-0.130-0.203-0.128166.03159.6518
2025Q32025-11-06-0.220-0.288-0.219149142.4718
2025Q22025-08-070.280-0.3700.277172.91139.4416
2025Q12025-05-08-0.280-0.467-0.280154.88133.1318
2024Q42025-02-12-0.400-0.299-0.403165.02159.7717
2024Q32024-10-29-0.300-0.329-0.296151.65156.8918
2024Q22024-08-08-0.320-0.479-0.316153.1150.0817
2024Q12024-04-30-0.500-0.500-0.502141.01142.2415
2023Q42024-02-15-0.410-0.349-0.413183.98182.7314
2023Q32023-11-02-0.790-0.460-0.790153.64151.312
2023Q22023-08-03-0.530-0.400-0.535146.82139.9712
2023Q12023-05-03-0.440-0.375-0.439134.29128.8212
2022Q42023-02-15-0.150-0.277-0.150156.23148.1711

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.800-0.614-0.325245.89240.58
2020FY-5.370-1.472-5.366298.85286.92
2021FY-0.530-0.463-0.528490.49493.74
2022FY-1.460-1.622-1.458516.41508.11
2023FY-2.180-2.137-2.177618.73616.72
2024FY-1.520-1.413-1.516610.79605.23
2025FY-0.350-0.426-0.350642.82636.44
2026FY--0.627--629.64
2027FY--0.672--703.27
2028FY--0.371--779.79
2029FY--0.095--860.61
2030FY-0.305--922.46

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0915130177.74170.51181.9
2026Q4S2026-11-0615120177.35170.51181.9
2026Q4S2026-11-051511171.35169177.2
2026Q4S2026-10-241511171.35169177.2
2026Q4S2026-10-221521171.35169177.2
2026Q4S2026-10-211521171.33169177.2
2026Q4S2026-10-161582171.33169177.2
2026Q4S2026-10-131582171.33169177.2
2026Q4S2026-10-121582171.33169177.2
2026Q4S2026-10-061582171.31169177.2
2026Q4S2026-09-301573170.99164.65177.2
2026Q4S2026-09-281573171.02164.65177.2
2026Q4S2026-09-181583171.02164.65177.2
2026Q4S2026-09-081582171.33164.65177.2

Estimate history

EPS, annual-0.197-1.18-0.325-5.366-0.528-1.458-2.177-1.516-0.349-0.5193
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.296-0.403-0.280.277-0.219-0.128-0.105-0.138-0.149
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual71.085146.313245.893298.845490.49516.409618.727610.785642.823618.58
Period201720182019202020212022202320242025TTM
Sales, quarterly151.654165.021154.883172.908149.002166.03150.843151.036150.667
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual95.3595.3596.242108.486112.515115.195119.095122.292127.691131.488
Period201720182019202020212022202320242025MRQ
Shares, quarterly121.04122.292123.134124.442126.54127.691128.988130.282131.488
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue618.58642.82610.78618.73516.41490.49298.85245.89146.31
Cost of Goods Sold Incl. D&A170.25190.38182.68209.41120.0974.0958.4761.0328.66
Gross Profit448.33452.45428.11409.31396.32416.40240.38184.86117.65
Selling, General and Administrative Excl. Other515.58544.08606.98611.18560.05469.31325.70213.93135.47
Research and Development222.54238.63264.00270.33264.27211.75123.3883.1047.54
Other Operating Expense3.688.5713.320.000.000.000.000.000.00
Operating Income-70.93-100.19-192.20-201.87-163.73-52.91-85.32-29.07-17.82
Interest Expense0.000.000.000.030.480.871.683.082.41
Unusual Expense-10.10-39.212.3663.464.22-0.66450.341.5092.94
Net Income Before Taxes-65.16-39.91-177.70-248.76-161.97-53.72-534.48-31.03-112.40
Income Taxes1.923.644.936.344.034.518.260.220.09
Consolidated Net Income-67.08-43.54-182.63-255.10-166.00-58.22-542.73-31.25-112.48
Net Income From Continuing Operations-67.08-43.54-182.63-255.10-166.00-58.22-542.73-31.25-112.48
Net Income-67.08-43.54-182.63-255.10-166.00-58.22-542.73-31.25-112.48
EPS (Recurring)-0.57-0.57-1.50-1.80-1.43-0.53-2.25-0.31-0.50
EPS (Basic, Before Extraordinaries)-0.52-0.35-1.52-2.18-1.46-0.53-5.37-0.32-1.18
EPS (Diluted)-0.52-0.35-1.52-2.18-1.46-0.53-5.37-0.32-1.18
EBITDA-29.70-56.38-148.49-158.25-130.72-24.66-66.30-22.00-13.92
Non-Operating Income (Expense)-4.3321.0816.8616.606.45-0.602.872.620.78
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense76.2985.96111.19131.89108.1170.0535.509.732.10
Price To Sales Ratio19.113.172.8310.608.0333.5147.9329.84-
Gross Margin72.4870.3870.0966.1576.7584.8980.4475.1880.41
Operating Margin-11.47-15.59-31.47-32.63-31.71-10.79-28.55-11.82-12.18
Net Margin-10.84-6.77-29.90-41.23-32.15-11.87-181.61-12.71-76.88
Shares Outstanding131.49127.69122.29119.10115.20112.51108.4996.2495.35
Market Capitalization8,195.308,195.301,738.356,614.984,171.0716,639.8715,237.157,332.997,321.45

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue150.67151.04150.84166.03149.00172.91154.88165.02
Cost of Goods Sold Incl. D&A36.8838.7343.6151.0248.1145.7745.4744.77
Gross Profit113.78112.30107.24115.01100.89127.14109.41120.25
Selling, General and Administrative Excl. Other128.98135.45123.22127.92132.55135.66153.87160.53
Research and Development52.9356.7956.8555.9757.1961.2264.2566.97
Other Operating Expense0.86-0.191.061.960.582.063.969.29
Operating Income-16.06-22.95-17.05-14.87-32.24-10.57-48.43-49.58
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-7.80-6.95-0.024.670.00-40.70-9.100.26
Net Income Before Taxes-18.48-18.64-12.85-15.19-28.2037.00-33.51-48.38
Income Taxes0.95-0.710.621.06-0.732.460.850.65
Consolidated Net Income-19.43-17.93-13.47-16.25-27.4734.54-34.36-49.03
Net Income From Continuing Operations-19.43-17.93-13.47-16.25-27.4734.54-34.36-49.03
Net Income-19.43-17.93-13.47-16.25-27.4734.54-34.36-49.03
EPS (Recurring)-0.19-0.18-0.11-0.10-0.220.05-0.33-0.40
EPS (Basic, Before Extraordinaries)-0.15-0.14-0.10-0.13-0.220.28-0.28-0.40
EPS (Diluted)-0.15-0.14-0.10-0.13-0.220.28-0.28-0.40
EBITDA-6.55-13.29-7.09-2.77-19.99-0.92-38.61-39.02
Non-Operating Income (Expense)-10.22-2.634.184.354.046.875.821.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense18.2520.2417.8919.9225.2627.2524.5525.71
Price To Sales Ratio19.118.084.263.222.292.241.712.86
Gross Margin75.5274.3671.0969.2767.7173.5370.6472.87
Operating Margin-10.66-15.20-11.30-8.96-21.64-6.12-31.27-30.04
Net Margin-12.89-11.87-8.93-9.79-18.4419.97-22.18-29.71
Shares Outstanding131.49130.28128.99127.69126.54124.44123.13122.29
Market Capitalization8,195.304,867.492,712.182,064.081,455.291,445.761,067.701,738.35

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments523.41393.40388.69432.62588.48680.17424.1765.0847.86
Short Term Receivables82.4987.86114.83104.2185.2551.2133.3728.0913.34
Inventories56.3483.1173.7181.6359.9729.9615.278.574.84
Other Current Assets22.2120.0218.7916.5813.9013.038.034.502.07
Total Current Assets684.45584.39596.02635.03747.59774.37480.84106.2468.11
Net Property, Plant & Equipment287.16309.94344.93359.21230.41119.8248.8211.136.92
Total Investments and Advances0.000.000.004.977.608.4752.335.010.00
Intangible Assets66.8420.1821.1327.3729.9122.3522.37--
Other Assets2.914.133.062.393.324.321.571.940.58
Total Assets1,041.37918.64965.141,028.981,018.83929.34605.92124.3175.61
Short Term Debt Incl. Current Port. of LT Debt10.989.2911.529.045.135.949.884.194.22
Accounts Payable12.7312.9115.7421.6017.354.7113.038.795.44
Income Tax Payable7.224.945.054.084.628.651.090.740.16
Other Current Liabilities122.5290.5094.8596.2483.2598.8339.0518.6412.31
Total Current Liabilities153.45117.63127.16130.96110.36118.1363.0532.3622.14
Long Term Debt73.3873.3383.8586.1476.8557.0419.84268.73164.75
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities18.2117.5413.096.1414.0515.10102.9543.201.23
Total Liabilities245.04208.50224.10223.24201.26190.27185.84344.30188.12
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity796.33710.13741.04805.74817.57739.07420.08-219.99-112.51
Total Shareholders Equity796.33710.13741.04805.74817.57739.07420.08-219.99-112.51
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity796.33710.13741.04805.74817.57739.07420.08-219.99-112.51
Total Liabilities & Stockholders Equity1,041.37918.64965.141,028.981,018.83929.34605.92124.3175.61
Book Value Per Share6.245.816.226.997.276.814.36-2.31-1.18
Tangible Book Value Per Share5.715.646.046.767.006.614.13-2.31-1.18
Full-Time Employees1,1781,3061,2591,2431,239852584390-
Price to Book Ratio9.872.408.885.3720.5020.7917.4717.39-
Return on Assets-4.44-19.39-25.59-16.21-5.98-70.70-8.56-112.53-
Return on Equity-5.78-25.17-32.98-20.45-7.48-93.64-31.24--
Return on Invested Capital-5.01-23.31-30.93-18.61-6.51-68.17-7.10-230.76-35.92
Quick Ratio4.094.264.114.236.236.307.383.022.86
Current Ratio4.464.974.694.856.776.567.633.283.08

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-67.08-43.54-182.63-255.10-166.00-58.22-542.73-31.25-112.48
Depreciation41.2343.8243.7143.6233.0128.2519.027.073.90
Other Funds (Non Cash)114.10110.84144.33178.94138.8196.04356.1914.054.16
Funds from Operations86.81111.115.41-32.545.8166.07-167.52-10.14-104.42
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital12.8924.941.2517.34-39.42-87.44-50.3844.7628.02
Cash from Operating Activities99.70136.056.66-15.20-33.61-21.37-217.9034.63-76.41
Capital Expenditures-5.93-5.93-13.39-49.52-131.66-101.28-38.39-42.77-6.71
Net Assets From Acquisitions-6.75-9.270.000.00-4.00-5.450.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments1.831.76-19.24183.02-215.230.000.000.000.00
Purchase of Investments-98.37-123.44-48.880.00-282.870.000.000.000.00
Sale Or Maturity of Investments100.20125.2029.64183.0267.640.000.000.000.00
Other Uses-0.500.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-11.35-13.44-32.63133.49-350.89-106.73-38.39-42.77-6.71
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock14.066.8010.9119.4821.2340.33506.01414.5986.63
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock14.066.8010.9119.4821.2340.33506.01414.5986.63
Proceedsfrom Stock Options0.000.000.000.000.000.00482.27410.8284.83
Issuance or Reduction of Debt, Net0.000.000.00-5.81-5.41-5.03-37.100.0018.74
Change in Long Term Debt0.000.000.00-5.81-5.41-5.03-37.100.0018.74
Issuance of Long Term Debt0.000.000.000.000.000.000.000.0019.51
Reduction of Long Term Debt0.000.000.00-5.81-5.41-5.03-37.100.00-0.77
Net Financing Active Other Cash Flow-8.690.000.000.000.000.000.000.000.00
Other Financing Activities Uses-8.690.000.000.000.000.000.000.000.00
Cash from Financing Activities5.376.8010.9113.6715.8235.30468.91414.59105.37
Exchange Rate Effect-0.240.48-0.16-0.03-0.040.23-0.46-0.04-0.02
Net Change in Cash93.48129.90-15.22131.93-368.72-92.57212.15406.4022.23
Free Cash Flow93.77130.12-5.73-63.80-165.27-122.65-254.56-8.12-82.69
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow126.0515.64-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments575.68552.03539.85523.41482.08447.26
Short Term Receivables58.7650.6356.1482.4996.59119.07
Inventories64.6352.6253.4956.3461.9668.97
Other Current Assets19.5719.3920.2622.2119.2020.36
Total Current Assets718.63674.67669.73684.45659.83655.66
Net Property, Plant & Equipment265.00272.01278.98287.16296.18302.41
Total Investments and Advances0.000.000.000.000.200.00
Intangible Assets65.5868.0864.4266.8469.2719.23
Other Assets13.9215.312.622.911.882.67
Total Assets1,063.131,030.071,015.761,041.371,027.36979.97
Short Term Debt Incl. Current Port. of LT Debt11.9512.0211.3310.9810.549.67
Accounts Payable21.5920.6917.4312.7318.0715.94
Income Tax Payable6.976.956.527.225.594.97
Other Current Liabilities99.8678.8578.32122.52113.1281.64
Total Current Liabilities140.37118.51113.60153.45147.32112.22
Long Term Debt63.8566.7870.0673.3876.4477.08
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities20.8819.2317.7818.2118.4817.39
Total Liabilities225.09204.52201.44245.04242.24206.69
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity838.04825.55814.32796.33785.12773.28
Total Shareholders Equity838.04825.55814.32796.33785.12773.28
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity838.04825.55814.32796.33785.12773.28
Total Liabilities & Stockholders Equity1,063.131,030.071,015.761,041.371,027.36979.97
Book Value Per Share6.376.346.316.246.206.21
Tangible Book Value Per Share5.875.815.815.715.666.06
Full-Time Employees---1,178--
Price to Book Ratio9.876.073.402.631.882.02
Return on Assets-6.42-7.47-2.36-4.44-7.77-8.86
Return on Equity-8.27-9.40-2.98-5.78-10.12-11.30
Return on Invested Capital-2.15-2.01-1.52-1.87-3.194.06
Quick Ratio4.665.255.424.094.065.23
Current Ratio5.125.695.904.464.485.84

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-19.43-17.93-13.47-16.25-27.4734.54
Depreciation9.509.669.9612.1012.259.65
Other Funds (Non Cash)32.6730.7324.3426.3526.6627.21
Funds from Operations22.7521.0320.8322.2011.4471.40
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-6.92-4.065.2918.5831.77-53.69
Cash from Operating Activities15.8316.9726.1240.7843.2117.71
Capital Expenditures-0.97-1.59-1.60-1.78-0.69-1.58
Net Assets From Acquisitions0.00-6.100.00-0.65-8.620.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.470.450.290.620.500.64
Purchase of Investments-24.53-24.55-24.71-24.58-49.50-49.36
Sale Or Maturity of Investments25.0025.0025.0025.2050.0050.00
Other Uses0.00-0.500.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.50-7.74-1.31-1.80-8.80-0.94
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock8.533.020.272.240.623.52
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock8.533.020.272.240.623.52
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-8.690.000.000.00
Other Financing Activities Uses0.000.00-8.690.000.000.00
Cash from Financing Activities8.533.02-8.422.240.623.52
Exchange Rate Effect-0.18-0.03-0.070.04-0.030.36
Net Change in Cash23.6812.2316.3241.2635.0020.65
Free Cash Flow14.8615.3924.5239.0042.5316.13
Price to Free Cash Flow126.0541.0422.2915.9317.9725.35

Revenue breakdown

Licensing And Royalty2024: 321.00K 2025: 46.14M
Service2024: 24.32M 2025: 32.73M
Single Cell - Instruments2024: 35.21M 2025: 22.67M
Single Cell Consumables2024: 372.31M 2025: 363.21M
Spatial - Consumables2024: 121.12M 2025: 143.98M
Spatial - Instruments2024: 57.50M 2025: 34.11M
Americas, Excluding United States2024: 13.45M 2025: 12.26M
Asia-Pacific, Excluding China2024: 45.96M 2025: 52.07M
China2024: 57.30M 2025: 70.26M
EMEA2024: 159.76M 2025: 161.72M
United States2024: 334.32M 2025: 346.51M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.74%12.5M116.2M3.40M
2026-10-1510.96%12.7M116.2M3.34M
2026-09-3013.23%15.4M116.2M3.03M
2026-09-1514.38%16.7M116.1M3.10M
2026-08-3113.93%16.2M116.1M3.25M
2026-08-1413.75%15.9M115.9M3.26M
2026-07-3113.82%15.6M113.1M3.15M
2026-07-1514.37%16.3M113.1M3.14M
2026-06-3014.45%16.3M113.1M3.02M
2026-06-1519.55%22.1M113.1M2.78M
2026-05-2914.62%16.5M112.8M2.56M
2026-05-1519.53%22.2M113.4M2.51M
2026-04-3014.26%16.2M114.0M2.55M
2026-04-1514.59%16.5M112.9M2.51M
2026-03-3114.19%16.0M112.9M2.61M
2026-03-1314.00%15.8M112.9M2.48M
2026-02-2714.52%16.4M112.9M2.49M
2026-02-1316.40%18.5M112.9M2.59M
2026-01-3014.55%16.3M112.2M2.68M
2026-01-1514.57%16.3M112.2M2.73M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5059.2062.5044.2624.99659.000.000.999-0.0190.000
call5.0056.7060.000.0014.8340.000.000.998-0.0210.001
call7.5054.2057.5048.3011.7020.000.000.998-0.0210.001
call10.0051.7055.000.009.8630.000.000.997-0.0220.001
call12.5049.2052.500.008.5760.000.000.993-0.0510.002
call15.0046.7050.0030.757.5911.000.000.992-0.0510.002
call17.5044.2047.5072.796.7967.000.000.991-0.0510.003
call20.0041.7045.0055.006.12931.000.000.990-0.0510.003
call22.5039.2042.5064.005.55640.000.000.989-0.0510.003
call25.0037.3040.0054.805.0521470.000.987-0.0510.003
call30.0031.7034.9034.804.12956410.000.969-0.1030.007
call35.0026.0030.0057.503.4811250.000.962-0.1000.008
call40.0021.8025.0023.752.86288.000.000.954-0.0960.010
call45.0017.0020.0018.272.3093031.000.942-0.0910.012
call50.0011.6015.409.681.9461220.000.923-0.0840.015
call55.007.3011.107.101.65141.000.000.746-0.2620.033
call60.003.907.606.501.4963260.000.635-0.2380.039
call65.001.803.703.301.1112296.000.475-0.2540.041
call70.001.451.901.701.0561,97329.000.300-0.1950.036
call75.000.751.100.901.1022,19214.000.191-0.1590.028
call80.000.000.800.421.2192713.000.137-0.1410.023
call85.000.000.450.301.2335944.000.084-0.1000.016
call90.000.100.600.181.4042784.000.076-0.1050.015
call95.000.001.150.051.5604023.000.070-0.1100.014
call1000.000.800.051.7043310.000.065-0.1140.013
call1050.000.800.051.8381380.000.061-0.1170.013
call1100.002.150.051.9641110.000.058-0.1200.012
call1150.002.151.152.06544.000.000.056-0.1230.012
call1200.002.150.052.19378.000.000.054-0.1260.011
call1250.002.150.152.29856.000.000.052-0.1280.011
call1300.002.150.552.39817.000.000.050-0.1300.011
call1350.002.150.052.4933.000.000.049-0.1320.010
call1400.002.150.302.58415.000.000.047-0.1340.010
put2.500.000.050.009.9580.000.00-0.003-0.0430.001
put5.000.000.050.027.5641410.00-0.004-0.0470.001
put7.500.000.050.626.2841.000.00-0.005-0.0480.002
put10.000.000.050.505.4161030.00-0.006-0.0490.002
put12.500.002.150.004.7850.000.00-0.007-0.0500.002
put15.000.000.250.014.48710.000.00-0.011-0.0680.003
put17.500.002.150.203.81443.000.00-0.009-0.0490.003
put20.000.002.150.053.43529.000.00-0.010-0.0490.003
put22.500.002.150.473.10319.000.00-0.011-0.0490.003
put25.000.000.300.032.8081170.00-0.013-0.0480.003
put30.000.002.150.122.7441150.00-0.031-0.1000.007
put35.000.002.150.152.24215.000.00-0.038-0.0960.008
put40.000.002.150.601.80336.000.00-0.046-0.0920.010
put45.000.002.100.431.41097.000.00-0.058-0.0860.012
put50.000.001.000.251.04741252.00-0.077-0.0790.015
put55.000.202.750.901.5342770.00-0.254-0.2560.033
put60.001.003.002.171.0766384.00-0.365-0.2310.039
put65.003.206.804.401.3724070.00-0.525-0.2460.041
put70.006.709.908.151.3185460.00-0.700-0.1870.036
put75.0010.9013.9012.301.3571991.00-0.809-0.1500.028
put80.0015.5018.6016.891.5211720.00-0.863-0.1320.023
put85.0020.3024.0026.701.8892320.00-0.916-0.0910.016
put90.0025.2028.4021.181.8765230.00-0.924-0.0960.015
put95.0030.1033.3037.332.01720.000.00-0.930-0.1000.014
put10035.1037.9027.001.9900.000.00-0.935-0.1030.013
put10540.1043.2016.502.2940.000.00-0.939-0.1060.013
put11045.1048.300.002.4870.000.00-0.942-0.1080.012
put11550.1053.300.002.6240.000.00-0.944-0.1100.012
put12055.1058.300.002.7530.000.00-0.946-0.1120.011
put12560.1063.300.002.8750.000.00-0.948-0.1140.011
put13065.1068.300.002.9900.000.00-0.950-0.1160.011
put13570.1073.300.003.1000.000.00-0.951-0.1170.010
put14075.1078.300.003.2050.000.00-0.953-0.1190.010

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-063Initial statement of beneficial ownership of securities2026-10-28SEC
2026-11-063Initial statement of beneficial ownership of securities2026-10-28SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-028-KCurrent report2026-10-28SEC
2026-10-07SCHEDULE 13G/ASEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-08SCHEDULE 13GSEC
2026-09-03144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-26144Filing for proposed sale of securities under Rule 144.SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09006.73M4
2026-08005.52M8
2026-070000
2026-06001.22M2
2026-05001.36M4
2026-0400122.78K1
2026-0300656.01K3
2026-0200638.01K4
2026-010000
2025-120000
2025-1100635.15K3

Institutional holders

Manager% owned
FMR LLC13.92%
BlackRock, Inc.8.51%
ARK Investment Management LLC7.88%
VANGUARD PORTFOLIO MANAGEMENT LLC5.50%
Quantinno Capital Management LP4.31%
VANGUARD CAPITAL MANAGEMENT LLC4.00%
PRICE T ROWE ASSOCIATES INC /MD/3.58%
Amova Asset Management Americas, Inc.3.30%
MORGAN STANLEY2.64%
GOLDMAN SACHS GROUP INC2.48%

Funds

Fund% owned
ARK Innovation ETF3.06%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.78%
ARK Genomic Revolution ETF2.44%
iShares Russell 2000 ETF2.39%
VANGUARD SMALL-CAP INDEX FUND2.01%
Select Medical Technology and Devices Portfolio1.54%
Strategic Advisers Fidelity U.S. Total Stock Fund1.27%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.16%
SMALLCAP World Fund Inc1.14%
VANGUARD EXTENDED MARKET INDEX FUND1.06%

OakChart. TXG. Cached 15 minutes.